Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose-Escalation Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
Conditions
Interventions
Sm-p80
Sm-p80 + GLA-SE
Locations
1
United States
Kaiser Permanente Washington Health Research Institute
Seattle, Washington, United States
Start Date
May 23, 2022
Primary Completion Date
March 19, 2024
Completion Date
March 19, 2024
Last Updated
July 14, 2025
NCT07484256
NCT07482215
NCT03910972
NCT06312462
NCT06828536
NCT06182176
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions